1E Therapeutics Overview
1E Therapeutics is a drug-development company creating RNA-targeting therapeutics based on a proprietary drug-design platform. 1E's process has proven able to develop drugs that address chronic life-threatening indications as well as emerging and evolving pathogens. 1E already has lead compounds that address a wide array of indications in oncology, age-related diseases, immunology, anti-microbial resistance, viral infections, and orphan neurological disorders.
Cumulative Funding Raised Over Time ($)
Latest News
growth-positive
Mysterious Israeli biotech company raises $120 million Seed round five months after founding
Israeli biotech company 1E Therapeutics has raised $120 million in a Seed funding round, making it the largest of its kind for an Israeli startup in the sector. The company, founded by Dr. Ido Bachelet, is focused on drug development and has hired a team of scientists. One of the major investors in the company is serial entrepreneur Marius Nacht, known for his involvement in the biotech and medtech sectors. 1E Therapeutics has a breakthrough drug development platform and already has lead compounds addressing various indications. The company is expanding its team and has advanced laboratories equipped with expensive equipment. It is actively seeking partnerships and has a basic website with contact information.
Investment
